159 related articles for article (PubMed ID: 2179758)
21. CD40 ligand expression on macrophages during peritonitis in continuous ambulatory peritoneal dialysis patients.
Yang X; Ye RG; Kong QY; Yang QQ; Gao Y; Zhong JH; Wang T
Adv Perit Dial; 2000; 16():213-5. PubMed ID: 11045296
[TBL] [Abstract][Full Text] [Related]
22. Intraperitoneal atrial natriuretic peptide increases peritoneal fluid and solute removal.
Wang T; Cheng HH; Heimbürger O; Chen C; Bergström J; Lindholm B
Kidney Int; 2001 Aug; 60(2):513-9. PubMed ID: 11473634
[TBL] [Abstract][Full Text] [Related]
23. [Pharmacokinetics of ceftazidime injected peritoneally in continuous ambulatory peritoneal dialysis].
Ryckelynck JP; Vergnaud M; Hurault de Ligny B; Allouche G; Malbruny B; Morel C
Pathol Biol (Paris); 1986 May; 34(5):328-31. PubMed ID: 3534700
[TBL] [Abstract][Full Text] [Related]
24. Pharmacokinetics of intraperitoneal cefotaxime treatment of peritonitis in patients on continuous ambulatory peritoneal dialysis.
Petersen J; Stewart RD; Catto GR; Edward N
Nephron; 1985; 40(1):79-82. PubMed ID: 4000338
[TBL] [Abstract][Full Text] [Related]
25. Comparative study of two different routes for insulin administration in CAPD diabetic patients. A multicenter study.
Selgas R; Diez JJ; Muñoz J; Miranda B; de Alvaro F; Rodriguez JC
Adv Perit Dial; 1989; 5():181-4. PubMed ID: 2577407
[TBL] [Abstract][Full Text] [Related]
26. [Peritonitis during continuous ambulatory peritoneal dialysis. Lavage treatment or not? A prospective study].
De Groc F; Rottembourg J; Jacq D; Jarlier V; N'Guyen J; Legrain M
Nephrologie; 1983; 4(1):24-7. PubMed ID: 6843764
[TBL] [Abstract][Full Text] [Related]
27. Effect of an L-carnitine-containing peritoneal dialysate on insulin sensitivity in patients treated with CAPD: a 4-month, prospective, multicenter randomized trial.
Bonomini M; Di Liberato L; Del Rosso G; Stingone A; Marinangeli G; Consoli A; Bertoli S; De Vecchi A; Bosi E; Russo R; Corciulo R; Gesualdo L; Giorgino F; Cerasoli P; Di Castelnuovo A; Monaco MP; Shockley T; Rossi C; Arduini A
Am J Kidney Dis; 2013 Nov; 62(5):929-38. PubMed ID: 23725973
[TBL] [Abstract][Full Text] [Related]
28. Persistent transforming growth factor-beta 1 expression may predict peritoneal fibrosis in CAPD patients with frequent peritonitis occurrence.
Lin CY; Chen WP; Yang LY; Chen A; Huang TP
Am J Nephrol; 1998; 18(6):513-9. PubMed ID: 9845827
[TBL] [Abstract][Full Text] [Related]
29. 1% amino acid peritoneal dialysate: single-cycle study in diabetic patients with end-stage renal disease.
Arfeen S; Goodship TH; Kirkwood A; Channon S; Ward MK
Am J Kidney Dis; 1994 Jan; 23(1):86-90. PubMed ID: 8285202
[TBL] [Abstract][Full Text] [Related]
30. Glucose, insulin and C-peptide kinetics during continuous ambulatory peritoneal dialysis.
Wideröe TE; Smeby LC; Myking OL; Wessel-Aas T
Proc Eur Dial Transplant Assoc; 1983; 20():195-200. PubMed ID: 6361735
[TBL] [Abstract][Full Text] [Related]
31. Serial changes of interleukin-6 and interleukin-8 levels in drain dialysate of uremic patients with continuous ambulatory peritoneal dialysis during peritonitis.
Lin CY; Lin CC; Huang TP
Nephron; 1993; 63(4):404-8. PubMed ID: 8459875
[TBL] [Abstract][Full Text] [Related]
32. Impact of dialysis duration and glucose absorption on nutritional indices in stable continuous ambulatory peritoneal dialysis patients.
Pajek J; Gucek A; Kveder R; Bucar-Pajek M; Kaplan-Pavlovcic S; Bren AF
J Ren Nutr; 2008 Nov; 18(6):503-8. PubMed ID: 18940653
[TBL] [Abstract][Full Text] [Related]
33. Effects of icodextrin on insulin resistance and adipocytokine profiles in patients on peritoneal dialysis.
Takeguchi F; Nakayama M; Nakao T
Ther Apher Dial; 2008 Jun; 12(3):243-9. PubMed ID: 18503703
[TBL] [Abstract][Full Text] [Related]
34. The determination of insulin sensitivity in hemodialysis and continuous ambulatory peritoneal dialysis in nondiabetic patients with end-stage renal disease.
Tuzcu A; Bahceci M; Yilmaz ME; Turgut C; Kara IH
Saudi Med J; 2005 May; 26(5):786-91. PubMed ID: 15951871
[TBL] [Abstract][Full Text] [Related]
35. Use of bolus intraperitoneal aminoglycosides for treating peritonitis in end-stage renal disease patients receiving continuous ambulatory peritoneal dialysis and continuous cycling peritoneal dialysis.
Mars RL; Moles K; Pope K; Hargrove P
Adv Perit Dial; 2000; 16():280-4. PubMed ID: 11045311
[TBL] [Abstract][Full Text] [Related]
36. Long-term clinical effects of a peritoneal dialysis fluid with less glucose degradation products.
Rippe B; Simonsen O; Heimbürger O; Christensson A; Haraldsson B; Stelin G; Weiss L; Nielsen FD; Bro S; Friedberg M; Wieslander A
Kidney Int; 2001 Jan; 59(1):348-57. PubMed ID: 11135090
[TBL] [Abstract][Full Text] [Related]
37. Transfer of native insulin through the peritoneal membrane during CAPD in non-diabetic and diabetic patients.
Ersoy FF; Karayalcin U; Karayalcin B; Sapan M; Bozcuk H; Süleymanlar G; Yakupoglu G
Adv Perit Dial; 1995; 11():119-22. PubMed ID: 8534683
[TBL] [Abstract][Full Text] [Related]
38. The alteration of dialysate cancer antigen 125 concentration under a biocompatible bicarbonate peritoneal dialysis solution and the preservation of the mesothelial cell viability.
Theodoridis M; Passadakis P; Kriki P; Gioka T; Panagoutsos S; Mourvati E; Thodis E; Kantartzi K; Vargemezis V
Ren Fail; 2008; 30(2):161-7. PubMed ID: 18300115
[TBL] [Abstract][Full Text] [Related]
39. High peritoneal residual volume decreases the efficiency of peritoneal dialysis.
Wang T; Cheng HH; Heimbürger O; Bergström J; Lindholm B
Kidney Int; 1999 May; 55(5):2040-8. PubMed ID: 10231469
[TBL] [Abstract][Full Text] [Related]
40. Long-term changes in transperitoneal water transport during continuous ambulatory peritoneal dialysis.
Wideröe TE; Smeby LC; Mjåland S; Dahl K; Berg KJ; Wessel Aas T
Nephron; 1984; 38(4):238-47. PubMed ID: 6514073
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
